Ainos Enrolls First Subject For Clinical Study Of VELDONA-Based Animal FCGS Drug; Dosing Of The First Subject Is Expected To Occur On July 26, 2024.
Ainos Enrolls First Subject For Clinical Study Of VELDONA-Based Animal FCGS Drug; Dosing Of The First Subject Is Expected To Occur On July 26, 2024.
The clinical study of new potential VELDONA-based animal drug is poised to expand VELDONA's market.
新潛力VELDONA動物藥物的臨床研究將擴大VELDONA的市場。
This clinical trial aims to complete the enrollment of 30 subjects by the end-2024 with the trial report to be finalized in Q1 2025.
該臨床試驗旨在通過招募30名受試者，於2024年底完成，並在2025年Q1完成試驗報告。
SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))))) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA"), today announced it has enrolled the first subject for its Taiwanese clinical study of VELDONA-based animal drug in treating feline chronic gingivostomatitis ("FCGS"), a serious and painful chronic cat oral disease characterized by inflammation or abnormal proliferation in the oral cavity. Dosing of the first subject is expected to occur on July 26, 2024.
加州聖地亞哥 / ACCESSWIRE / 2024年7月23日 / Ainos公司（納斯達克：AIMD，AIMDW）（"Ainos"或"公司"），一家專注於新型人工智能點-即時診斷測試（"POCT"）和低劑量干擾素治療（"VELDONA"）的綜合醫療保健公司，今天宣佈已經在臺灣招募了第一個FCGS患者進行基於VELDONA的動物藥物臨床研究,用於治療貓的慢性齦口炎（"FCGS"），這是一種口腔嚴重和疼痛的慢性貓口腔疾病，其特徵爲口腔腔內的炎症或異常增殖。第一個病人的劑量預計將在2024年7月26日發生。
